secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senseonics Holdings, Inc. (SENS)
CIK:        0001616543
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001104659-24-029373
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senseonics Q4 revenue $8.0M (+44% YoY); net loss $17.2M; 365-day FDA submission planned
--------------------------------------------------------------------------------

- Q4 2023 revenue $8.0M vs $5.6M Q4 2022; full-year revenue $22.4M (+37% YoY).
- Net loss $17.2M ($0.03/sh) in Q4 2023 vs net income $11.6M in Q4 2022; loss driven by derivative accounting.
- Medicare expanded Eversense E3 coverage via three MACs; UnitedHealthcare coverage secured.
- ENHANCE pivotal trial completed; 365-day system FDA submission expected in coming weeks; potential Q4 2024 launch.
- First half 2024 revenue outlook ~$10M (+16% YoY); full-year guide deferred to Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1616543/000110465924029373/0001104659-24-029373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1616543/000110465924029373/tm247542d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer